Section 1 - CHEMICAL PRODUCT AND COMPANY IDENTIFICATION

PRODUCT NAME
Clofibrate

STATEMENT OF HAZARDOUS NATURE

SYNONYMS
Flammability: 1
Toxicity: 2
Body Contact: 3
Reactivity: 1
Chronic: 2

Min/Nil=0
Low=1
Moderate=2
High=3
Extreme=4
CANADIAN WHMIS SYMBOLS

EMERGENCY OVERVIEW

RISK
Risk of serious damage to eyes.
May cause SENSITISATION by skin contact.
Harmful by inhalation, in contact with skin and if swallowed.
Toxic to aquatic organisms, may cause long-term adverse effects in the aquatic environment.

POTENTIAL HEALTH EFFECTS

ACUTE HEALTH EFFECTS

SWALLOWED
- Accidental ingestion of the material may be harmful; animal experiments indicate that ingestion of less than 150 gram may be fatal or may produce serious damage to the health of the individual.
- Chlorophenoxy compounds irritate the digestive system and cause nausea and vomiting, chest pain, and diarrhea. Taking large doses can result in mineral imbalance, temperature changes, hyperventilation, low blood pressure, dilated blood vessels, damage to the heart and liver with death of white blood cells, and convulsions.
- Side-effects of clofibrate intake include nausea, gastrointestinal discomfort (with diarrhoea), drowsiness, headache, dizziness, weight-gain, pruritus, skin rash, alopecia, leucopenia, pancreatitis and cardiac arrhythmias. A rise in serum aminotransferase values may also occur following clofibrate treatment; hepatomegaly (enlarged liver) has been reported though this seems not to be associated with hepatotoxicity. Similar side-effects have been seen in some clofibrate analogues.

EYE
- If applied to the eyes, this material causes severe eye damage.

SKIN
- Skin contact with the material may be harmful; systemic effects may result following absorption.
- The liquid may be miscible with fats or oils and may degrease the skin, producing a skin reaction described as non-allergic contact dermatitis. The material is unlikely to produce an irritant dermatitis as described in EC Directives.
- Open cuts, abraded or irritated skin should not be exposed to this material.
- 2,4-D and its derivatives can all be absorbed through the skin of humans. Severe peripheral neuropathy has followed causing limb paralysis and loss of sensation.

INHALED
- Inhalation of aerosols (mists, fumes), generated by the material during the course of normal handling, may be harmful.
- The material is not thought to produce respiratory irritation (as classified using animal models). Nevertheless, inhalation of vapors, fumes or aerosols, especially for prolonged periods, may produce respiratory discomfort and occasionally, distress.
- Inhalation of chlorophenoxy dusts or mists may result in sore throat, burning sensations in the throat and chest, cough, tears, inflamed nose, dizziness and inco-ordination, as a result of absorption from the lungs.

CHRONIC HEALTH EFFECTS
- There has been concern that this material can cause cancer or mutations, but there is not enough data to make an assessment.

Skin contact with the material is more likely to cause a sensitization reaction in some persons compared to the general population.
Limited evidence suggests that repeated or long-term occupational exposure may produce cumulative health effects involving organs or biochemical systems.

Clofibrate was tested carcinogenicity by oral administration in the diet of rats and mice. In rats clofibrate produced hepatocellular carcinomas.
Clofibrate was tested in several experiments by combined administration with other chemicals. It enhanced the hepatocarcinogenicity of N-nitrosamines in rats and hamsters. It did not enhance the carcinogenicity of 2-acetylaminofluorene in rat liver.
Chlorophenoxy herbicides cause an increased risk of cancers of soft tissue, lymph and bronchi. Inflammation of skin can result from long term contact.

Section 3 - COMPOSITION / INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>NAME</th>
<th>CAS RN</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>clofibrate</td>
<td>637-07-0</td>
<td>&gt;98</td>
</tr>
</tbody>
</table>
Section 4 - FIRST AID MEASURES

SWALLOWED
· IF SWALLOWED, REFER FOR MEDICAL ATTENTION, WHERE POSSIBLE, WITHOUT DELAY. · Where Medical attention is not immediately available or where the patient is more than 15 minutes from a hospital or unless instructed otherwise:
  
  **EYE**
  · If this product comes in contact with the eyes: · Immediately hold eyelids apart and flush the eye continuously with running water. · Ensure complete irrigation of the eye by keeping eyelids apart and away from eye and moving the eyelids by occasionally lifting the upper and lower lids.
  
  **SKIN**
  · If skin contact occurs: · Immediately remove all contaminated clothing, including footwear · Flush skin and hair with running water (and soap if available).
  
  **INHALED**
  · If fumes or combustion products are inhaled remove from contaminated area. · Lay patient down. Keep warm and rested.

**NOTES TO PHYSICIAN**
· Treat symptomatically.

Following exposures to chlorophenoxy compounds:
· Acute toxic reactions are rare. The by-product of production, dioxin, may be implicated in subacute features such as hepatic enlargement, chloracne, neuromuscular symptoms and deranged porphyrin metabolism.
· Large intentional overdoses result in coma, metabolic acidosis, myalgias, muscle weakness, elevated serum creatine kinase, myoglobinuria, irritation of the skin, eyes, respiratory tract and gut and mild renal and hepatic dysfunction.
Extensively bound to plasma protein. 85% of a daily dose can be recovered from urine mostly as the glucuronide.

Section 5 - FIRE FIGHTING MEASURES

<table>
<thead>
<tr>
<th>Vapour Pressure (mmHG):</th>
<th>Negligible</th>
</tr>
</thead>
<tbody>
<tr>
<td>Upper Explosive Limit (%):</td>
<td>Not available.</td>
</tr>
<tr>
<td>Specific Gravity (water=1):</td>
<td>Not available</td>
</tr>
<tr>
<td>Lower Explosive Limit (%):</td>
<td>Not available</td>
</tr>
</tbody>
</table>

**EXTINGUISHING MEDIA**
· Foam.
· Dry chemical powder.

**FIRE FIGHTING**
· Alert Emergency Responders and tell them location and nature of hazard.
· Wear full body protective clothing with breathing apparatus.
When any large container (including road and rail tankers) is involved in a fire, consider evacuation by 100 metres in all directions.

**GENERAL FIRE HAZARDS/HAZARDOUS COMBUSTIBLE PRODUCTS**
· Combustible.
· Slight fire hazard when exposed to heat or flame.
Combustion products include: carbon dioxide (CO2), hydrogen chloride, phosgene, other pyrolysis products typical of burning organic material.

**FIRE INCOMPATIBILITY**
· Avoid contamination with oxidizing agents i.e. nitrates, oxidizing acids, chlorine bleaches, pool chlorine etc. as ignition may result.

**PERSONAL PROTECTION**
Glasses:
Chemical goggles.
Gloves:
Respirator:
Type A Filter of sufficient capacity

Section 6 - ACCIDENTAL RELEASE MEASURES

**MINOR SPILLS**
· Environmental hazard - contain spillage.
· Clean up waste regularly and abnormal spills immediately.
· Avoid breathing dust and contact with skin and eyes.
· Wear protective clothing, gloves, safety glasses and dust respirator.
· Use dry clean up procedures and avoid generating dust.
· Vacuum up or sweep up. NOTE: Vacuum cleaner must be fitted with an exhaust micro filter (HEPA type) (consider explosion-proof machines designed to be grounded during storage and use).
· Dampen with water to prevent dusting before sweeping.
• Place in suitable containers for disposal.

MAJOR SPILLS
- Environmental hazard - contain spillage.
- Moderate hazard.
- Clear area of personnel and move upwind.
- Alert Emergency Responders and tell them location and nature of hazard.

Section 7 - HANDLING AND STORAGE

PROCEDURE FOR HANDLING
- DO NOT allow clothing wet with material to stay in contact with skin.
- Avoid all personal contact, including inhalation.
- Wear protective clothing when risk of exposure occurs.

RECOMMENDED STORAGE METHODS
- Glass container.
- Packaging as recommended by manufacturer.
- Check that containers are clearly labelled.
- Tamper-proof containers.
- Polyethylene or polypropylene containers.
- Metal drum with sealed plastic liner.
- Metal can or drum
- Packing as recommended by manufacturer.

STORAGE REQUIREMENTS
- Store in original containers.
- Keep containers securely sealed.

Section 8 - EXPOSURE CONTROLS / PERSONAL PROTECTION

EXPOSURE CONTROLS
The following materials had no OELs on our records
- clofibrate: CAS:637-07-0

PERSONAL PROTECTION

RESPIRATOR
Type A Filter of sufficient capacity
Consult your EHS staff for recommendations

EYE
- When handling very small quantities of the material eye protection may not be required.
- For laboratory, larger scale or bulk handling or where regular exposure in an occupational setting occurs:
  - Chemical goggles
  - Face shield. Full face shield may be required for supplementary but never for primary protection of eyes
  - Contact lenses may pose a special hazard; soft contact lenses may absorb and concentrate irritants. A written policy document, describing the wearing of lens or restrictions on use, should be created for each workplace or task. This should include a review of lens absorption and adsorption for the class of chemicals in use and an account of injury experience. Medical and first-aid personnel should be trained in their removal and suitable equipment should be readily available. In the event of chemical exposure, begin eye irrigation immediately and remove contact lens as soon as practicable. Lens should be removed at the first signs of eye redness or irritation - lens should be removed in a clean environment only after workers have washed hands thoroughly. [CDC NIOSH Current Intelligence Bulletin 59].

HANDS/FEET
- NOTE: The material may produce skin sensitization in predisposed individuals. Care must be taken, when removing gloves and other protective equipment, to avoid all possible skin contact.
- Suitability and durability of glove type is dependent on usage. Important factors in the selection of gloves include: such as:
  - frequency and duration of contact,
  - chemical resistance of glove material,
  - glove thickness and
dexterity
Select gloves tested to a relevant standard (e.g. Europe EN 374, US F739).
· When prolonged or frequently repeated contact may occur, a glove with a protection class of 5 or higher (breakthrough time greater than 240 minutes according to EN 374) is recommended.
· When only brief contact is expected, a glove with a protection class of 3 or higher (breakthrough time greater than 60 minutes according to EN 374) is recommended.
· Contaminated gloves should be replaced.
   Gloves must only be worn on clean hands. After using gloves, hands should be washed and dried thoroughly. Application of a non-perfumed moisturiser is recommended.
· Rubber gloves (nitrite or low-protein, powder-free latex). Employees allergic to latex gloves should use nitrile gloves in preference.
· Double gloving should be considered.
· PVC gloves.
· Protective shoe covers.
· Head covering.

OTHER
· For quantities up to 500 grams a laboratory coat may be suitable.
· For quantities up to 1 kilogram a disposable laboratory coat or coverall of low permeability is recommended. Coveralls should be buttoned at collar and cuffs.
· For quantities over 1 kilogram and manufacturing operations, wear disposable coverall of low permeability and disposable shoe covers.
· For manufacturing operations, air-supplied full body suits may be required for the provision of advanced respiratory protection.
· Eye wash unit.
· Ensure there is ready access to an emergency shower.
· For Emergencies: Vinyl suit.

ENGINEERING CONTROLS
■ Enclosed local exhaust ventilation is required at points of dust, fume or vapor generation.
HEPA terminated local exhaust ventilation should be considered at point of generation of dust, fumes or vapors.

---

**Section 9 - PHYSICAL AND CHEMICAL PROPERTIES**

**PHYSICAL PROPERTIES**

<table>
<thead>
<tr>
<th>State</th>
<th>Melting Range (°F)</th>
<th>Boiling Range (°F)</th>
<th>Flash Point (°F)</th>
<th>Decomposition Temp (°F)</th>
<th>Autoignition Temp (°F)</th>
<th>Upper Explosive Limit (%)</th>
<th>Lower Explosive Limit (%)</th>
<th>Volatile Component (%vol)</th>
<th>Molecular Weight</th>
<th>Viscosity</th>
<th>pH (1% solution)</th>
<th>pH (as supplied)</th>
<th>Vapour Pressure (mmHG)</th>
<th>Specific Gravity (water=1)</th>
<th>Relative Vapor Density (air=1)</th>
<th>Evaporation Rate</th>
<th>Decomposition Temp (°F)</th>
<th>Upper Explosive Limit (%)</th>
<th>Lower Explosive Limit (%)</th>
<th>Volatile Component (%vol)</th>
<th>Molecular Weight</th>
<th>Viscosity</th>
<th>pH (1% solution)</th>
<th>pH (as supplied)</th>
<th>Vapour Pressure (mmHG)</th>
<th>Specific Gravity (water=1)</th>
<th>Relative Vapor Density (air=1)</th>
<th>Evaporation Rate</th>
</tr>
</thead>
</table>
| Liquid         | Not available     | 309.2-312.8 (20 mm) | >230             | Not available           | Not available         | Not available          | Not available            | Negligible                | 242.7           | Not applicable | Not applicable | Not applicable | Negligible | Not applicable | >1                     | Not applicable       | Not available          | Not available          | Not available          | Not applicable | Not applicable          | 242.7           | Not applicable | Not applicable | Not applicable | Negligible | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Not available          | Not available          | Not available          | Not available          | Not available          | Not available          | Not applicable | Not applicable | Not applicable | Not applicable | Negligible | Not applicable | Not applicable | Not applicable | Not applicable | Not available | Not available          | Not available          | Not available          | Not available          | Not available          | Not available          | Not applicable | Not applicable | Not applicable | Not applicable | Negligible | Not applicable | Not applicable | Not applicable | Not applicable | Not available | Not available          | Not available          | Not available          | Not available          | Not available          | Not available          | Not applicable | Not applicable | Not applicable | Not applicable | Negligible | Not applicable | Not applicable | Not applicable | Not applicable | Not available | Not available          | Not available          | Not available          | Not available          | Not available          | Not available          | Not applicable | Not applicable | Not applicable | Not applicable | Negligible | Not applicable | Not applicable | Not applicable | Not applicable | Not available | Not available          | Not available          | Not available          | Not available          | Not available          | Not available          | Not applicable | Not applicable | Not applicable | Not applicable | Negligible | Not applicable | Not applicable | Not applicable | Not applicable | Not available | Not available          | Not available          | Not available          | Not available          | Not available          | Not available          | Not applicable | Not applicable | Not applicable | Not applicable | Negligible | Not applicable | Not applicable | Not applicable | Not applica...
TOXICITY

IRRITATION

Oral (rat) LD50: 940 mg/kg

Intraperitoneal (rat) LD50: 910 mg/kg

Oral (mouse) LD50: 1220 mg/kg

Intraperitoneal (mouse) LD50: 540 mg/kg

Intravenous (mouse) LD50: >500 mg/kg

Oral (rabbit) LD50: 1370 mg/kg

Oral (g.pig) LD50: 1280 mg/kg

Oral (hamster) LD50: 2400 mg/kg

Intraperitoneal (hamster) LD50: 1260 mg/kg

Oral (mammal) LD50: 3000 mg/kg

Contact allergies quickly manifest themselves as contact eczema, more rarely as urticaria or Quincke's edema. The pathogenesis of contact eczema involves a cell-mediated (T lymphocytes) immune reaction of the delayed type.

Fibrates are a class of amphiphilic carboxylic acids. They are used for a range of metabolic disorders, mainly hypercholesterolaemia (high cholesterol), and are therefore hypolipidaemic agents.

**Fibrates are agonists of the PPAR-α receptor in muscle, liver, and other tissues. Activation of PPAR-α signaling results in:**

- Increased beta-oxidation in the liver
- Decreased hepatic triglyceride secretion
- Increased lipoprotein lipase activity, and thus increased VLDL (Very Low Density Lipoprotein) clearance
- Increased HDL (High Density Lipoprotein)
- Increased clearance of remnant particles
- Most fibrates can cause mild stomach upset and myopathy (muscle pain with CPK elevations). Since fibrates increase the cholesterol content of bile, they increase the risk for gallstones.

In combination with statin drugs, fibrates cause an increased risk of rhabdomyolysis, idiosyncratic destruction of muscle tissue, leading to renal failure. A powerful statin drug, cerivastatin (Lipobay), was withdrawn because of this complication. The less lipophilic statins are less prone to cause this reaction, and are probably safer when combined with fibrates.

Fibrates are structurally and pharmacologically related to the thiazolidinediones, a novel class of anti-diabetic drugs that also act on PPARs (more specifically PPARγ).

Adverse clinical effects have been reported for 7% of the exposures to thiazolidinediones, the most frequent of which were hypoglycemia (2%), hyperglycaemia (1%), and drowsiness (1%).

Oedema is an adverse event associated with thiazolidinedione therapy. The potential for mild-to-moderate peripheral oedema with thiazolidinedione is known, especially in patients who have heart failure or use insulin.

Vary rarely, reports of new onset or worsening (diabetic) macular oedema with decreased visual acuity have been reported with the use of thiazolidinediones.

Subcutaneous benign adipose tissue tumours (lipomas) have been observed in rats treated with thiazolidinedione drugs, and are probably related to the pharmacodynamic activity of this drug class. Urinary bladder tumours were probably secondary to formation of urinary calculi, and are unlikely to pose a carcinogenic risk in humans.

Tremor, convulsions, muscle weakness, ataxia, diaphoresis, musculoskeletal changes, effects on fertility, foetolethality, effects on newborn recorded.

CARCINOGEN

<table>
<thead>
<tr>
<th>CLOFIBRATE</th>
<th>US Environmental Defense Scorecard Recognized Carcinogens</th>
<th>Reference(s)</th>
<th>P65</th>
</tr>
</thead>
</table>

CLOFIBRATE | US Environmental Defense Scorecard Suspected Carcinogens | Reference(s) | P65 |

Section 12 - ECOLOGICAL INFORMATION

Toxic to aquatic organisms, may cause long-term adverse effects in the aquatic environment.

This material and its container must be disposed of as hazardous waste.

Avoid release to the environment.

Refer to special instructions/ safety data sheets.

Ecotoxicity

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>Persistence: Water/Soil</th>
<th>Persistence: Air</th>
<th>Bioaccumulation</th>
<th>Mobility</th>
</tr>
</thead>
<tbody>
<tr>
<td>clofibrate</td>
<td>HIGH</td>
<td>LOW</td>
<td>MED</td>
<td></td>
</tr>
</tbody>
</table>
Section 13 - DISPOSAL CONSIDERATIONS

US EPA Waste Number & Descriptions

B. Component Waste Numbers

When clofibrate is present as a solid waste as a discarded commercial chemical product, off-specification species, as a container residue, or a spill residue, use EPA waste number U240 (waste code T).

For discarded unused formulations containing clofibrate use hazardous waste number F027.

When clofibrate is present as a solid waste as a discarded commercial chemical product, off-specification species, as a container residue, or a spill residue, use EPA waste number U240 (waste code T).

For discarded unused formulations containing clofibrate use hazardous waste number F027.

When clofibrate is present as a solid waste as a discarded commercial chemical product, off-specification species, as a container residue, or a spill residue, use EPA waste number U240 (waste code T).

For discarded unused formulations containing clofibrate use hazardous waste number F027.

When clofibrate is present as a solid waste as a discarded commercial chemical product, off-specification species, as a container residue, or a spill residue, use EPA waste number U240 (waste code T).

For discarded unused formulations containing clofibrate use hazardous waste number F027.

When clofibrate is present as a solid waste as a discarded commercial chemical product, off-specification species, as a container residue, or a spill residue, use EPA waste number U240 (waste code T).

For discarded unused formulations containing clofibrate use hazardous waste number F027.

Disposal Instructions

All waste must be handled in accordance with local, state and federal regulations.

Puncture containers to prevent re-use and bury at an authorized landfill.

Legislation addressing waste disposal requirements may differ by country, state and/or territory. Each user must refer to laws operating in their area. In some areas, certain wastes must be tracked.

A Hierarchy of Controls seems to be common - the user should investigate:

- Reduction
- Reuse
- Recycling
- Disposal (if all else fails)

This material may be recycled if unused, or if it has not been contaminated so as to make it unsuitable for its intended use. If it has been contaminated, it may be possible to reclaim the product by filtration, distillation or some other means. Shelf life considerations should also be applied in making decisions of this type. Note that properties of a material may change in use, and recycling or reuse may not always be appropriate.

DO NOT allow wash water from cleaning equipment to enter drains. Collect all wash water for treatment before disposal.

- Recycle wherever possible or consult manufacturer for recycling options.
- Consult Waste Management Authority for disposal.

Section 14 - TRANSPORTATION INFORMATION

DOT:
Symbols: G Hazard class or Division: 9
Identification Numbers: UN3082 PG: III
Label Codes: 9 Special provisions: 8, 146, 335, IB3, T4, TP1, TP29

8 of 9
Section 15 - REGULATORY INFORMATION

clofibrate (CAS: 637-07-0) is found on the following regulatory lists;

Section 16 - OTHER INFORMATION

ND
Substance CAS Suggested codes clofibrate 637-07-0

Reasonable care has been taken in the preparation of this information, but the author makes no warranty of merchantability or any other warranty, expressed or implied, with respect to this information. The author makes no representations and assumes no liability for any direct, incidental or consequential damages resulting from its use. For additional technical information please call our toxicology department on +800 CHEMCALL.

Classification of the preparation and its individual components has drawn on official and authoritative sources as well as independent review by the Chemwatch Classification committee using available literature references. A list of reference resources used to assist the committee may be found at: www.chemwatch.net/references.

The (M)SDS is a Hazard Communication tool and should be used to assist in the Risk Assessment. Many factors determine whether the reported Hazards are Risks in the workplace or other settings. Risks may be determined by reference to Exposures Scenarios. Scale of use, frequency of use and current or available engineering controls must be considered.

This document is copyright. Apart from any fair dealing for the purposes of private study, research, review or criticism, as permitted under the Copyright Act, no part may be reproduced by any process without written permission from CHEMWATCH. TEL (+61 3) 9572 4700.

Issue Date: Nov-15-2009
Print Date: Jan-14-2011